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THYROID FUNCTION AND DYSFUNCTION
THYROSIM App for Education and Research Predicts
Potential Health Risks of Over-the-Counter
Thyroid Supplements
Simon X. Han,1 Marisa Eisenberg,2 P. Reed Larsen,3 and Joseph DiStefano III1
Background: Computer simulation tools for education and research are making increasingly effective use of the
Internet and personal devices. To facilitate these activities in endocrinology and metabolism, a mechanistically
based simulator of human thyroid hormone and thyrotropin (TSH) regulation dynamics was developed and
further validated, and it was implemented as a facile and freely accessible web-based and personal device
application: the THYROSIM app. This study elucidates and demonstrates its utility in a research context by
exploring key physiological effects of over-the-counter thyroid supplements.
Methods: THYROSIM has a simple and intuitive user interface for teaching and conducting simulated ‘‘what-
if’’ experiments. User-selectable ‘‘experimental’’ test-input dosages (oral, intravenous pulses, intravenous
infusions) are represented by animated graphical icons integrated with a cartoon of the hypothalamic–pituitary–
thyroid axis. Simulations of familiar triiodothyronine (T3), thyroxine (T4), and TSH temporal dynamic re-
sponses to these exogenous stimuli are reported graphically, along with normal ranges on the same single
interface page; and multiple sets of simulated experimental results are superimposable to facilitate comparative
analyses.
Results and Conclusions: This study shows that THYROSIM accurately reproduces a wide range of published
clinical study data reporting hormonal kinetic responses to large and small oral hormone challenges. Simulation
examples of partial thyroidectomies and malabsorption illustrate typical usage by optionally changing thyroid
gland secretion and/or gut absorption rates—expressed as percentages of normal—as well as additions of oral
hormone dosing, all directly on the interface, and visualizing the kinetic responses to these challenges.
Classroom and patient education usage—with public health implications—is illustrated by predictive simulated
responses to nonprescription thyroid health supplements analyzed previously for T3 and T4 content. Notably, it
was found that T3 in supplements has potentially more serious pathophysiological effects than does T4—
concomitant with low-normal TSH levels. Some preparations contain enough T3 to generate thyrotoxic con-
ditions, with supernormal serum T3-spiking and subnormal serum T4 and TSH levels and, in some cases, with
normal or low-normal range TSH levels due to thyroidal axis negative feedback. These results suggest that
appropriate regulation of these products is needed.
Introduction
We previously developed, implemented and demon-strated the utility of a physiologically-based computer
simulation model of human thyroid hormone (TH) regulation
in blood, tissues and the hypothalamic-pituitary-thyroid axis
(1–4). It was built and quantified from published human
data, validated against other published human data not used
in its development, and its utility for predictively exploring
quantitative pharmacological, pathophysiological, and Food
and Drug Administration (FDA) policy issues has been es-
tablished for several normal and abnormal conditions in
adults and children (1–5). To date, it has been demonstrated
that this model accurately reproduces a wide range of clinical
study data, illustrating hormonal kinetic responses to large
and small oral hormone challenges (1–5). Its potential for
addressing a broader class of applications, however, has not
yet been exploited by others, no doubt in part because exer-
cising this moderately complex simulation model requires
higher-level mathematical expertise. Regrettably, despite
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being mechanistically and clinically derived and motivated,
this neuroendocrine system teaching and research tool has not
been accessible to most endocrinologists. Remedying this is a
major goal of this study.
This study describes THYROSIM, a novel simulation tool
based on this model, implemented as a user-friendly web
application (app) and globally accessible via the Internet.
THYROSIM has been developed primarily for researchers,
teachers, clinicians, and others interested in and more or less
familiar with the workings of TH regulation. Modern compu-
tational and Internet technology tools have been exploited for
facilitating the complex human interface issues. Only pictures,
graphs, and familiar clinical science language and quantitative
ideas are used on the app interface—no higher math is required.
It is offered as an accessible tool for research and teaching
about the dynamic regulation of this multi-feedback system in
health and disease, as well as a tool for patient education.
First, the embedded simulation model is further validated
with additional published clinical data not used in model de-
velopment, which demonstrably extends its potential appli-
cability in the clinic, research laboratory, and classroom. Then
the practical utility of the THYROSIM simulator for interac-
tively teaching and conducting simulated ‘‘what-if’’ experi-
ments is demonstrated using examples of current clinical and
public health import. Several ‘‘what-if’’ simulations of plasma
hormone responses for hypothetical dosing of subjects with
levothyroxine, or with non-prescription ‘‘thyroid support
supplements’’ are presented, several of which have been found
to contain liothyronine and/or T4 in clinically significant
amounts (6). THYROSIM is used to simulate the effects of
these oral dosage supplements on circulating thyroxine (T4),
triiodothyronine (T3), and thyrotropin (TSH) in normal adults.
The results suggest that some of these over-the-counter (OTC)
‘‘supplements’’ will induce significant perturbations in cir-
culating THs and that appropriate regulation of these
products is needed to prevent serious health consequences,
including thyrotoxicosis.
The THYROSIM web app is freely available via all major
web browsers, including Internet Explorer, Google Chrome,
Mozilla Firefox, Apple Safari, and Amazon Silk, making
THYROSIM available on a variety of personal devices and
tablets (e.g., iPhone, iPad, Android, Kindle, Nook) as well
as laptop and desktop computers. It is fully accessible from
user (client) computers or devices by remotely connecting to
the UCLA (server) website at: http://biocyb1.cs.ucla.edu/
thyrosim. All interaction is done locally in the user’s browser.
All computations are done on the UCLA server. There is
nothing to download.
An Android OS-based version of THYROSIM is also
being made available as a self-contained app. It is available
by request from the corresponding author, and will be made
available for free download at the Google apps website.
The mathematical model embedded in THYROSIM is re-
presented by 13 ordinary differential equations (ODEs), 12
additional algebraic equations describing various terms in the
ODEs, 3 output measurement equations and more than 50
physiological parameters (5). All are given in the Supple-
mentary Data (Supplementary Data are available online at
www.liebertpub.com/thy), along with free access to compu-
ter code in several forms. Technical details of the computer
simulator implementation and interaction software also are
given in the Supplementary Data.
Materials and Methods
THYROSIM: what it is and how it works
A full screenshot of the animated cartoon and results in-
terface is shown in Figure 1. Brief directions for use are
opened at the top of the screen. All simulation results are
given quantitatively on the right-hand side of the interface,
graphed as familiar T3, T4, and TSH temporal dynamic re-
sponses, each with normal-range bands shown in yellow/
crosshatched. T4, T3, and TSH are graphed separately, in
familiar unit scales, so that individual responses can be better
visualized and compared. On a computer, hovering the mouse
over graphed results generates a label containing numerical
(time and concentration) values of the nearest point, as il-
lustrated in Figure 1, where T3 = 1.16 at 1.85 days.
Figure 1 includes two sets of example results. The first
are the built-in example graphs, run from the top of the
screen—a simulation of normal TH dynamics over a five-
day period (solid blue curves). The dashed green curves are
for a superimposed ‘‘what-if’’ experiment described further
below.
The cartoon image on the upper left-hand side of Figure 1
represents the whole body (pink oval), brain and feedback
system components, and exogenous entry pathways that in-
clude absorption of oral inputs through the gut and intrave-
nous (IV) pulse and infusion inputs. The top far-left is where
exogenous T3 and T4 (TH) input stimuli are specified by the
user. Each TH has an oral input (pill) icon, IV pulse (syringe)
icon, and IV infusion (IV bag) icon. Inputs are color-coded
(T3 is blue and T4 is green) so they are easily distinguished.
When an input is added, an associated animation is shown.
Oral input stimuli, by default, require dose, dosing interval,
and start and end day values, all entered in the bottom-half of
the interface. An IV-pulse input requires dose and start day.
IV-infusion inputs require dose and start and end day values,
also entered in the bottom-half of the interface. Multiple
inputs—different doses, different doses at different times,
and so on—are entered as needed for the experiment being
simulated; they simply expand the list at the bottom as they
are added.
Simulating ‘‘what-if’’ experiments
Adjusting secretion and absorption. Users can simulate a
spectrum of abnormal as well as normal thyroid conditions,
including hypo- and hyperthyroidism and malabsorption, by
adjusting T3 and T4 secretion and absorption rates. Controls
for T4/T3 secretion/absorption rate changes are located be-
neath the center image. These can be adjusted to simulate
abnormal states (change the values directly in the box or via
scrollbars by clicking on the orange-white ‘‘+’’). Euthyroid
(default) conditions are defined as 100% (T4 secretion), 88%
(T4 absorption); 100% (T3 secretion) and 88% (T3 absorp-
tion) (1,2), and simulation steady-state initial conditions
(ICs) are precomputed to accelerate the numerical solution
process. Nominal absorption percentages were estimated
from real pharmacokinetic data (7) in Eisenberg et al. (1).
When T4/T3 secretion/absorption values are changed, the
dynamics of the system are different, and the default behavior
is to recalculate ICs. Users also have the option to use eu-
thyroid steady-state IC values, which can be useful for sim-
ulating a change in a patient condition, for example for
simulating hormone dynamics after thyroidectomy.
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To begin a simulated experiment, users enter test-input and
other simulation ‘‘what-if’’ experimental conditions into
their web browser via the single-screen graphic interface, as
described above and further below. This input is validated
(silently) and, if needed, the web application alerts the user to
make corrections or prompts the remote UCLA server to
begin simulating the model experiment. A program on the
server parses the input from the user-client and generates
internal commands to execute the model solver on the server.
The model ODEs are solved numerically using the open-
source, freely available ODE solver in OCTAVE (8). (Details
are given in the Supplementary Data.) When simulation is
complete, results are sent back to the user’s browser, and
plasma T4, T3, and TSH time-course responses to the sim-
ulated test-inputs are graphed on the user interface screen, as
in Figure 1. Computations are done in molar units and hor-
monal output results are converted to lg/L or mU/L for T4,
T3 and TSH time-course plotting on the screen.
For example, the dashed green hormone results curves in
Figure 1 simulate a hemi-thyroidectomy. This ‘‘what-if’’
experiment was done by first adjusting the thyroidal secretion
rates to 50%, setting the slider positions halfway in the lower
part of Figure 1. ‘‘Recalculate Initial Conditions’’ was then
unchecked for the hemi-thyroidectomy condition, so both
sets of results used euthyroid ICs. The experimental goal was
to observe the dynamic responses following surgical hemi-
thyroidectomy in an otherwise euthyroid individual.
The dashed green curve graphs display T4, T3, and TSH
dynamic responses to the simulated experiment. The T4 and
T3 graphs show small oscillations. T4 decreases very slowly,
whereas T3 levels fall briefly at first, but then increase and
continue to approach the solid euthyroid steady-state line
slowly. For TSH, oscillations are stable for the euthyroid
solid simulation curve, whereas the green dashed curve re-
sponse show oscillations with increasing mean values, il-
lustrating the effects on ‘‘axis’’ negative feedback.
Implementing and comparing different exogenous input
quantities and schedules. Typical THYROSIM usage in-
volves simulating and comparing plasma hormone response
dynamics, following simulated ‘‘what-if’’ exogenous exper-
imental stimuli, including oral, IV-pulse and IV-infusion
hormone treatment options. For easy comparisons, the in-
terface superimposes two sets of simulation results—a key
feature of ‘‘what-if’’ experimentation—in two different col-
ors (blue and green; one dashed, the other solid), as exem-
plified for hypothetical patient-education situations and
hormone absorption comparisons in the Results section.
THYROSIM allows single or multiple exogenous test-input
stimuli at user-specified doses and times, and simulation time
can be extended to a maximum of 100 days. For example, a
user can explore different T4 and/or T3 dosages that might be
given orally to reestablish euthyroid conditions over different
time intervals (e.g., a month or two) in a hypothetical primary
FIG. 1. Single-page
screenshot of the web appli-
cation, showing graphical
interface for implementing
simulation experiments, with
hormonal responses to two
‘‘what-if’’ experiments: (i)
euthyroid steady-state condi-
tions; (ii) response to simu-
lated surgical hemi-
thyroidectomy (see text),
both over five days. Detailed
hormone concentrations at
any time are available by
hovering the mouse over the
plots, as shown for triiodo-
thyronine (T3) at time
1.58 days. DIRECTIONS
for using the app and an
EXAMPLE are directly
accessible at the top of the
single interface page, as
shown.
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hypothyroid patient with 50% or other percent residual thy-
roidal secretion. Simulation time and pill quantity and fre-
quency adjustments are made on the lower part of the
interface page, populated as a user adds inputs. Added inputs
(e.g., T4 or T3 doses) are arranged in chronological order
based on these times. The simulation is then partitioned into
intervals using these times as boundaries. ICs for each in-
terval are adjusted by the amount of exogenous input at the
specific time point, and each interval is then executed as a
separate simulation increment. For IV-infusion inputs, the
endpoint is also used as a boundary. Controls for deleting,
enabling, and disabling inputs are provided. Results from
each interval are aggregated, and all are displayed as a con-
tinuum and as a single experimental outcome on graphs of
T4, T3, and TSH temporal dynamic responses, as illustrated
in Figure 1 and later in Figures 5–8.
TH absorption as well as secretion rates can be changed,
with exogenous inputs (oral, IV pulse, and IV infusion) added
and/or removed to explore ‘‘abnormal’’ responses to differ-
ent experimental inputs and conditions, as illustrated fur-
ther below.
Results
Additional validation studies: kinetic responses in
plasma to various oral dose preparations—simulated
versus measured
The physiologically based TH feedback control system
model upon which the THYROSIM simulator was developed
was validated against real kinetic data not used in model
quantification in earlier publications (1–5). All comparisons
with T3 and/or T4 dosing in hypothyroid and euthyroid adults
and children provided strong validation of the accuracy of
THYROSIM plasma hormone kinetic responses over a broad
range of test inputs, up to 600lg of oral T4 and 75 lg of
T3 dosing and other conditions (1–5). Several of these are
illustrated in Figure 2, with details described in the figure
legend. Additional simulation studies with THYROSIM are
compared here, with real TH kinetic data reported in several
additional publications involving human oral dosing experi-
ments (9–11).
Figure 3A and B compares THYROSIM predicted serum
T3 concentrations (solid curves) to serum T3 concentration
data after oral administration of desiccated thyroid containing
99lg T3 (Fig. 3A) or 75lg synthetic T3 (Cytomel; Fig. 3B),
respectively (9) (T4 content was 363lg; plasma T4 kinetic
response was not reported for this study). Serum T3 concen-
trations (solid squares), measured over 26 hours, followed real
dosing at those levels (fig. 1 in LeBoff et al.) (9). Figure 3A
predicted levels are quite similar to measured serum T3, with
the same peak values and area under the curve (AUC). The
Figure 3B curve also has about the same peak value and AUC
of the serum data, anticipating the data somewhat, suggesting
possibly delayed absorption of the synthetic T3 dose in these
subjects studied at a different time, or a delayed release rate of
T3 from the Cytomel preparation.
In LeBoff et al. (9), figures 2 and 3 provided plasma T3 or
T4 kinetic response data for two additional studies involving
oral dosing with TH. The second study (fig. 2 in LeBoff et al.)
(9) was performed with synthetic T3 (75 lg Cytomel), or
FIG. 2. Sample THYROSIM validation studies completed previously (1–5). (A) Data (circles) and predicted plasma
thyrotropin (TSH) response curve (mU/L) to 75lg of oral T3 (from fig. 9 in Eisenberg et al.) (2). (B) Predicted plasma TSH
curve (mU/L) versus plasma TSH data from three individuals (fig. 8 in Eisenberg et al.) (2). (C) Predicted steady-state TSH
(mU/L), T3 (lg/L), and thyroxine (T4; lg/dL; numerical values on y-axis) in euthyroid and hypothyroid (TX) patients treated
with 150lg of levothyroxine (circles) versus data (triangles) and clinical ranges (adapted from fig. 7 in Eisenberg et al.) (2).
FIG. 3. One-day simulated
kinetic response curves versus
measured results (squares) in
plasma to (A) 99lg T3 in oral
desiccated thyroid, or to (B)
75lg synthetic oral T3 (Cyto-
mel) from LeBoff et al. (9).
The disparity between data and
simulation in the subject
shown in (B) is postulated to
be due to delayed absorption
or dissolution of the synthetic
T3 (Cytomel) preparation.
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with desiccated thyroid (five grains equivalent, Proloid)
containing 275 lg of T4 + 99 lg of T3, and serum T3 levels
were measured over 26 hours. In the third study, desiccated
thyroid (six grains equivalent, Armour) containing 363lg
of T4 + 99lg of T3 was administered, and plasma T4 re-
sponses were measured over 26 hours again, all within the TH
ranges for which THYROSIM was developed. Close agree-
ment in all cases further validate THYROSIM predic-
tions after near-physiological range doses. THYROSIM also
closely reproduced results of a similar study by Snyder and
Utiger (10) (see their fig. 2), who gave combined daily oral
doses of synthetic TH over four weeks to normal subjects at
two different levels—15 lg of T3+ 60 lg of T4 and 30 lg of
T3 + 120lg of T4—and measured both plasma T3 and T4
levels over the last 24 hours of treatment. Data from Snyder
and Utiger (10) and model agreement simulations are pro-
vided in Figures S3 and S4 of the Supplementary Data.
Research and education applications of THYROSIM
Testing different degrees of thyroid gland secretion loss.
The dynamical simulation curves in Figure 4 illustrate kinetic
hormonal responses in serum over 30 days resulting from day-
zero reductions of glandular secretion, first from 100% to 10%
(solid blue curves), and then from 100% to 1% (dashed green
curves). Secretion rates of 1% shown in Figure 4 are for the
second (dashed curve green) run. One percent residual secre-
tion is within the remnant ranges reported after thyroidectomy
in Lal et al. (12) and in the authors’ own post-thyroidectomy
results reported in Eisenberg et al. (4). TSH values quickly
become and remain clearly overtly hypothyroid for both re-
ductions, with values also consistent with previously published
data (4). T4 and T3 values become distinctly subnormal for 1%
secretion; for 10% secretion, they fall to the low end of the
normal range, all as illustrated by the yellow/crosshatched-
band normal ranges in the graphs.
Testing oral hormone absorption differences. This ex-
ample compares THYROSIM results using different assump-
tions about oral hormone absorption fractions. THYROSIM
default values for the percent of oral hormone absorbed in
normal human subjects are 88% for both T3 and T4, estimated
from real pharmacokinetic (PK) data in 33 normal volunteers
fasted over 10 hours (1,7). Figure 2 of Kaplan et al. (13)
provided serum T4 concentration data over five weeks in
normal subjects given daily 75lg T3 doses for four weeks.
Assuming 88% absorption of the daily T3 doses, the simu-
lated T4 response shown in Figure 5 (dashed green curves)
falls too steeply with respect to the serum T4 data over the
four weeks of treatment. However, at 50% absorption (solid
blue curves), it tracks the T4 data fairly well. The cessation
of daily T3 dosing raises the suppressed TSH back into the
normal range by reducing the negative feedback effect of
added T3, as also noted for the T3 and T4 dynamics in week
5. With no mention of diet in Kaplan et al. (13), it is sus-
pected that these not-fasted subjects ate normally, possibly
reducing the absorption of T3.
The added value in Figure 5 is the simulation response
graphs of unmeasured T3 and TSH concentrations in the
study subjects, predicting exceedingly large abnormal re-
sponses, especially in T3 spiking and suppressed and tran-
siently spiking TSH responses, reflecting mild thyrotoxic
conditions for this T3 dosing pattern.
Patient education/public health application: predicted en-
docrinological responses to some OTC ‘‘thyroid health’’
supplements. Kang et al. (6) recently measured the T3 and
T4 content of 10 thyroid dietary supplements available
commercially without prescription. They found highly
variable amounts of T3 and/or T4 in all but one, and clini-
cally relevant amounts of both in the majority of them, some
exceeding common treatment dosages for hypothyroidism.
They emphasized the importance of patient and provider
FIG. 4. THYROSIM simulator demonstration experiments, illustrating 100% (start) down to 10% or to 1% thyroidal
secretion changes at time zero and their 30-day responses to these reductions. The timing and severity of hypothyroidism is
reflected in all three plots.
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education regarding use of such readily available supple-
ments, unregulated by the FDA or other agency monitor-
ing hormone content. The consequences of their findings
were simulated on TH dynamics of otherwise hypothetical
euthyroid and hypothyroid individuals taking the re-
commended dosages for one month. Several of these sim-
ulated experiments are illustrated in Figures 6–8, with
all simulated dosages and month-long hormonal responses
to them within the validated ranges of applicability of
THYROSIM.
Figure 6 depicts simulated kinetic responses over a month
for a hypothetical euthyroid subject with no supplementa-
tion (solid blue curve) versus superimposed responses to
oral dosing with T3-only supplement #4—two tablets twice
daily, each containing *8 lg of T3 (*32 lg T3/day)—as
directed by the manufacturer (from table 1 of Kang et al.)
(6), and begun on day 2 (dashed green curve). With no
supplement (solid blue curves), TSH, T3, and T4 are in the
middle of their normal ranges. With supplements (dashed
green curves), T4 concentrations become subnormal within
a week, and T3-doubling spikes are present within a day. In
contrast, TSH initially dips below normal and then rises to
the low-normal range. Results (not shown) differed only
slightly for a simulated hypothyroid subject with 50% thy-
roid secretory function.
Figure 7 depicts simulated kinetic responses in hypo-
thetical euthyroid subjects over a month to two different
OTC supplements begun on day 2, one containing 25.4 lg of
T3 + 8.57 lg of T4, once daily (#9 solid blue curves), the other
10 lg of T3 only, twice daily (#5 green dashed curves), also as
directed by the manufacturer (from table 1 of Kang et al.) (6).
With either supplement, abnormal T3-doubling spikes are
present within a day, and T4 concentrations become subnor-
mal within a week. In contrast, TSH concentrations after
transient dips remain in the low-normal range in response to
either supplement. These results suggested eliminating the
8.57 lg of T4 dose in another simulation run (not shown),
which gave nearly superimposed results. Physiologically, the
small amount of T4 in the preparation had little or no effect on
TH dynamics compared with the relatively large dose of T3.
Figure 8 depicts simulated kinetic responses in hypo-
thetical euthyroid subjects over a month to two different
combination T3 +T4-containing OTC supplements, again
with dosing begun on day 2. The first had 1.83 lg of
T3 + 5.77 lg of T4 three times daily (#2 solid blue curves);
the other had 4.13 lg of T3 and 22.9 lg of T4 four times
FIG. 5. Simulated versus
measured (T4 only) hormone
kinetic responses to 75lg of
T3 daily dosing for four
weeks in euthyroid subjects
(13). The solid blue curves
assume 50% and the dashed
green curves assume 88%
absorption of the T3 dose,
which was not reported in the
published study (13). Normal
range bands are shown in
yellow/crosshatched. Weekly
measured standard error of
the mean range data are
shown superimposed on the
T4 plot (from fig. 2 of Ka-
plan et al.) (13). The predic-
tive simulation response
graphs of unmeasured T3 and
TSH concentrations (added
value) illustrate exceedingly
large abnormal T3 spiking
and suppressed and tran-
siently spiking TSH re-
sponses, reflecting mild
thyrotoxic conditions for this
T3 dosing pattern.
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daily (#3 green dashed curves), each as directed by the
manufacturer (from table 1 of Kang et al.) (6). With either
supplement, T4 and T3 levels remain in the mid- to high-
normal ranges, as does TSH for the low-TH dosing (#2). In
contrast, for the high-dose T4 supplement (#3), TSH falls to
below normal values and remains there, in the ‘‘thyrotoxic’’
range, during treatment.
Discussion
We created THYROSIM as an intuitive and friendly user
interface for exercising a sophisticated and mechanistically-
based human TH feedback regulation model. The imbedded
model accurately represents average adult populations, hav-
ing been quantified and validated primarily from euthyroid
FIG. 6. Supplement effects:
simulated kinetic responses
over a month for hypothetical
euthyroid subjects with no
supplementation versus oral
dosing begun on day 2 with
over-the-counter (OTC) sup-
plement #4, two tablets twice
daily, each tablet containing
*8lg of T3 only (*32lg
T3/day), as directed by the
manufacturer. Normal range
bands are shown in yellow/
crosshatched. With no sup-
plement (solid blue curves),
TSH, T3, and T4 are in the
middle of their normal ranges.
With supplements (dashed
green curves), T4 concentra-
tions become subnormal
within a week, and serum T3
spikes are present within a
day. In contrast, TSH initially
dips below normal and then
rises to the low-normal range.
Supplement hormone content
values are from table 1 of
Kang et al. (6).
FIG. 7. Supplement effects:
simulated kinetic responses in
hypothetical euthyroid sub-
jects over a month to two
different supplements, begun
on day 2, one containing
25.4lg of T3+ 8.57lg of T4
once daily (#9, solid blue
curves), the other 10lg of T3
only, twice daily (#5, green
dashed curves). Normal range
bands are shown in yellow/
crosshatched. With either
supplement, T4 concentra-
tions become subnormal
within a week, and abnormal
T3 spiking is present within a
day. In contrast, TSH initially
dips below normal and then
rises to the low-normal range
in response to either supple-
ment. Supplement hormone
content values are from table
1 of Kang et al. (6).
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volunteer subject data. This facile simulation tool functions
as a freely accessible Internet (web) application, for use by
anyone with an Internet connection and an interest in normal
and perturbed TH regulation dynamics. By releasing THYR-
OSIM as a web application, access is thus offered to the widest
possible audience, not for clinically prescribing treatment, but
for use as a research, teaching, and patient education tool.
Potentially useful information about hypothetical treatments
with hormone or hormone-containing substances can be
gleaned from it, as has been illustrated above and is discussed
further below.
THYROSIM requires minimal quantitative skills, and is
especially useful for performing intuitive, hypothetical,
‘‘what-if’’ experiments. It includes basic graphical tools to
set up numerous ‘‘what-if’’ simulation experiments—useful
primarily for better understanding and teaching human TH
regulation, for example in a physiology or medical or
pharmacology school course, or in a patient education sit-
uation—graphically illustrating effects of non-adherence,
for example, on circulating hormone levels. Oral hormone
inputs can be simulated as either single doses, repeated
period (e.g., daily) doses of T4 and/or T3, and so on, sim-
ulating typical (or experimental) therapeutic dosing regi-
mens. Users also can simulate IV-pulse and IV-infusion
input dosing, or combinations thereof, with options to de-
lete, edit, or temporarily disable/enable any input. Simula-
tion of common abnormal conditions is accomplished by
simply adjusting percentages of TH secretion (0–200%) and
gut absorption (0–100%), for example secretion for com-
pletely thyroidectomized patients can be set to 0%. For
these simulated patients, it is possible to see how thyroid-
ectomy changes TH levels by not recalculating ICs and
setting the simulation to start at euthyroid (100%) values.
For simulated hypo/hyperthyroid patients, recalculating ICs
would likely be preferred to setting them to start from eu-
thyroid steady-state conditions, since they might have been
in their respective abnormal states for some time. This
means a user could simulate a hypothetical patient with no
TH secretion for an extended period of time, even if such a
patient might more realistically have been hospitalized and
treated before the end of the simulation time.
THYROSIM users only need a modern browser and Internet
connection. It works directly with Microsoft Internet Explorer
v9 and above, Google Chrome, Apple Safari, Amazon Silk,
and Mozilla Firefox browsers. This Internet app is thus func-
tional on handheld smart phones and tablets such as the Google
or Samsung Android, Apple iPhone/iPad/iPod, Nook, and
Amazon Kindle, as well as laptop and desktop computers
running any of these browsers. A self-contained version of the
THYROSIM app, not requiring an Internet connection, is also
available for Android devices and has been distributed to
several endocrinologists in the United States and Europe.
FIG. 8. Supplement effects: simulated kinetic responses over a month to two different T3–T4 combination OTC sup-
plements, each begun on day 2 in hypothetical euthyroid subjects, one containing 1.83 lg of T3+ 5.77 lg of T4 three times
daily (#2, blue curves), the other 4.13 lg of T3 and 22.9 lg of T4 four times daily (#3, green curves), as directed by the
manufacturer. Normal range bands are shown in yellow/crosshatched. With either supplement, T4 and T3 levels remain
in the mid- to high-normal ranges, as does TSH for the low-TH dosing (#2), attributed to axis feedback providing
appropriate regulation in response to the relatively low T4 dose in supplement #2. In contrast, for the high-dose T4
supplement (#3), TSH falls to below normal values and remains there, in the ‘‘thyrotoxic’’ range, during treatment.
Supplement hormone content values are from table 1 of Kang et al. (6).
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In earlier work (1–5), the simulator was shown to reproduce
all experimental results published in the several papers on
which it is based and was also validated against several not
used in its development, as illustrated in part in Figure 2. It has
been further validated here against data from several additional
published studies using oral dosing regimens with both T3 and
T4, two of these illustrated in Figures 3 and 4. Validations and
other examples have shown how the comparison and normal
range features can be used to check predicted hormone dy-
namics visually in different thyroid states or under different
treatment protocols. These controls provide broad flexibility in
designing a variety of ‘‘what-if’’ experiments—simulated
studies that sharpen intuition as well as knowledge about the
dynamics of this neuroendocrine system.
The use of THYROSIM has been illustrated in several
typical applications, quantifying T3, T4, and TSH kinetic
responses after simulated (i) thyroid surgery (Figs. 1 and 4),
(ii) daily dosing with different oral TH preparations (Figs. 3
and 5), (iii) altered hormone absorption (Fig. 5), and (iv)
dosing of euthyroid subjects with TH-containing supple-
ments (Figs. 6–8). These ‘‘what-if’’ experiments mimicked
the effects of several OTC preparations containing various
quantities of TH, measured and reported in a previous pub-
lication (6) but untested objectively in experimental subjects,
which has been accomplished here by simulation of hypo-
thetical subjects receiving these supplements.
Notably, the OTC supplement simulations indicate that the
T3 content in supplement pills has a potentially greater
pathophysiological effect on TSH concentrations than does
T4, leading to abnormal T3-spiking and substantial and
sustained reductions in T4 levels (Figs. 6 and 7). In additional
test simulations (not shown), it was found that the small
amount of T4 (*9 lg) in Figure 7 pills had little effect on the
kinetics; it was the T3 (*25lg) in the tablets that had the
major quantitative effect.
In Figure 8, both multi-dose OTC supplement combina-
tions, totaling *6 lg of T3 + 17 lg of T4 and 16 lg of
T3 + 92 lg of T4 daily, altered TH levels, but not in all ways
anticipated. Neither combination resulted in values outside
normal ranges for plasma T3 or T4, whereas TSH was
substantially suppressed for the larger (92 lg) but not the
smaller (17 lg) dose of T4 in the combinations supplements,
the smaller but not the larger dose effect compensated by
axis feedback.
These kinds of ‘‘what-if’’ experiments—the major goal of
predictive simulation models—provide guidance on what
might be expected if these unregulated preparations were
used as suggested on their labels. The results with preparation
#4 (Fig. 6), for example—dosing with a total of*32 lg of T3
per day in a hypothetical euthyroid or hypothyroid individ-
ual—would substantially reduce serum T4 due to feedback
effects and would raise mean serum T3 well above the normal
range, possibly causing mild thyrotoxicosis and certainly
making thyroid function tests difficult to interpret. In con-
trast, other preparations would not affect serum TH concen-
trations nearly as much, due to the reduction in endogenous
TH secretion through negative feedback at the hypothalamic/
pituitary level. Thus, they would not, as implied, ‘‘supple-
ment’’ thyroid function. It is of course not clear whether these
OTC products might be purchased by individuals seeking
to induce increases in metabolic rate, or by those who were
either properly or self-diagnosed as being hypothyroid. Since
the current understanding of thyroid physiology suggests
that circulating T4 is required to provide adequate supplies
of T3 to the central nervous system, and that even mild thy-
rotoxicosis may have adverse effects on cardiac and bone
health, this information might deter their use as well as
demonstrate their potential toxicity to the appropriate regu-
latory agencies (14).
Results in Figures 6–8 also underscore the need to
measure serum T4 and T3 as well as TSH levels in patients
who may be ingesting hormonal T4 or T3 in OTC ‘‘thyroid
support’’ supplements, information possibly not provided
to their physicians. THYROSIM results suggest that thy-
roidal axis negative feedback can mask such perturba-
tions, maintaining TSH levels in the normal or low-normal
range.
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